Plasminogen-activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells.
about
Suppression of breast cancer growth and metastasis by a serpin myoepithelium-derived serine proteinase inhibitor expressed in the mammary myoepithelial cellsEssential role of TGF-beta/Smad pathway on statin dependent vascular smooth muscle cell regulation.Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants.A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.Overexpression of plasminogen activator inhibitor 2 in human melanoma cells inhibits spontaneous metastasis in scid/scid miceCellular localization of type 1 plasminogen activator inhibitor messenger RNA and protein in murine renal tissueRelationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumours.Significance of plasminogen activator inhibitor 2 as a prognostic marker in primary lung cancer: association of decreased plasminogen activator inhibitor 2 with lymph node metastasisInhibitory effects of malotilate on invasion and metastasis of rat mammary carcinoma cells by modifying the functions of vascular endothelial cells.Plasminogen activator inhibitor type 2 in breast cancer.Immunohistochemical expression of SKALP/elafin in squamous cell carcinoma of the oesophagusPlasminogen activator-dependent pericellular proteolysis.Protumorigenic activity of plasminogen activator inhibitor-1 through an antiapoptotic functionMaspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells.In vivo patterns of expression of urokinase and its inhibitor PAI-1 suggest a concerted role in regulating physiological angiogenesis.Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosisPlasminogen activator inhibitor-1 (PAI-1) modifies the formation of aggressive fibromatosis (desmoid tumor).Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model.Characterization of matrix-degrading proteinases and their inhibitors secreted by human gynecological carcinoma cells.A regulatory element that mediates co-operation between a PEA3-AP-1 element and an AP-1 site is required for phorbol ester induction of urokinase enhancer activity in HepG2 hepatoma cells.The biochemistry of cancer dissemination.Thrombin neutralizes plasminogen activator inhibitor 1 (PAI-1) that is complexed with vitronectin in the endothelial cell matrix.Modulation of urokinase and urokinase receptor gene expression in human renal cell carcinoma.Plasminogen activator inhibitor type 1 interacts with alpha3 subunit of proteasome and modulates its activity.Plasminogen activator inhibitor-1 and -3 increase cell adhesion and motility of MDA-MB-435 breast cancer cells.A novel 3-dimensional culture system as an in vitro model for studying oral cancer cell invasion.Localization of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, 2 and plasminogen in colon cancer.Inhibitory role of plasminogen activator inhibitor-1 in invasion and proliferation of HLE hepatocellular carcinoma cells.
P2860
Q22009110-F7D1F7B7-C381-413D-903F-E452CF0F03FEQ33393631-6EB10E0B-FDA9-4444-BECF-C210C5F9BBE5Q33886514-B7B9AF98-290B-4AC4-9303-674A1F84D5DEQ33907027-E8B3CAD5-B960-4CDD-B513-9225ADAD0EA9Q34832169-BD487751-1F4B-4E26-B855-5316EC4C055BQ35832540-402C9C13-59DE-4BB0-8D07-9C69C773CE5DQ35993235-3B481FC4-F197-41AA-B171-EA87C1BCD329Q36114916-08A1BDD4-6E61-40E5-9A2C-076FA5DD922CQ36292528-E4F7C8CB-9701-4179-8BD6-D2A91C64EBC4Q36430997-78553792-C7F4-40E7-8194-C4EB625CECF8Q36431252-C6776D17-0ACA-4935-B1FD-8803B99D6321Q36457877-85FAC5AE-14BB-42DB-9FEE-7853FBEE90DAQ36486880-32B5C7D8-9129-4330-945F-A150E2C3F804Q37264167-F5F091AD-67D4-486D-A2B9-38E8078C2442Q37293011-79EBA442-F6E3-461B-9CA6-579FE7B1E1BBQ38274802-99EB3D18-5924-4C27-868F-469941556A8FQ38331352-0F510799-9BED-44D3-BE7C-56E7BAD5B31AQ40395907-7B4ECBFE-1F26-4FDC-B77A-7A3CB6AF2858Q41263250-706DC6FA-9313-4A5A-B548-09CF7AAF8BC8Q41340665-68AC3D25-37F9-4EC9-94B7-0EF3419634DAQ41546059-1CF4193D-C18E-4CEC-B543-7838EEB9B609Q41547351-A16E87F9-4642-489B-A83E-077A2F3E2AA6Q41821669-8956FEAC-FF76-4755-9DA8-F5586C39F79DQ42064350-68220156-979E-4908-9348-923E42E59FFCQ42109406-25704F79-CADE-43D3-85CB-1E9DC2EF56ABQ44102084-74B2C349-3B55-4258-B711-B80F62BC8F8EQ46725605-4002EA0B-F3E6-452C-B0EB-4ACBA776B0CBQ49164116-8BE2904E-2D3B-4F78-A335-41C530C1D57CQ54969476-2C3564FB-870D-4831-9C2D-5FD9EDD912B8
P2860
Plasminogen-activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells.
description
1990 nî lūn-bûn
@nan
1990 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1990 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
name
Plasminogen-activator inhibito ...... oma and colon carcinoma cells.
@ast
Plasminogen-activator inhibito ...... oma and colon carcinoma cells.
@en
type
label
Plasminogen-activator inhibito ...... oma and colon carcinoma cells.
@ast
Plasminogen-activator inhibito ...... oma and colon carcinoma cells.
@en
prefLabel
Plasminogen-activator inhibito ...... oma and colon carcinoma cells.
@ast
Plasminogen-activator inhibito ...... oma and colon carcinoma cells.
@en
P2093
P2860
P356
P1476
Plasminogen-activator inhibito ...... oma and colon carcinoma cells.
@en
P2093
Bergonzelli GE
Kruithof EK
Medcalf RL
P2860
P304
P356
10.1073/PNAS.87.18.6939
P407
P577
1990-09-01T00:00:00Z